196
Participants
Start Date
August 31, 2011
Primary Completion Date
December 31, 2013
Study Completion Date
June 30, 2014
MM-121
MM-121 IV at 40 mg/mg loading dose on Cycle 1, Week 1 followed by 20 mg/mg weekly for all subsequent doses
Paclitaxel
Standard dosing of paclitaxel IV, followed by standard dosing of doxorubicin IV plus cyclophosphamide IV, followed by surgery.
Virginia Oncology Associates, Norfolk
Cancer Center of the Carolinas, Greenville
Piedmont Healthcare, Altanta
Piedmont Fayette Hospital, Fayetteville
Georgia Cancer Specialists, Marietta
Florida Cancer Research Institute, Plantation
Universito of Birmingham atAlabama, Birmingham
Beaumont Health Systems, Royal Oak
University Of Chicago, Chicago
Illinois Cancer Specialists, Niles
Texas Oncology - Garland, Garland
Texas Oncology - Lewisville, Lewisville
Texas Oncology - Medical City, Dallas
Texas Oncology - Dallas, Dallas
Texas Oncology - Baylor Charles A Sammons Cancer Center, Dallas
Texas Oncology - Tyler, Tyler
Texas Oncology - Bedford, Bedford
Texas Oncology - Memorial City, Houston
Cancer Care Centers of South Texas, San Antonio
Texas Oncology - McAllen, McAllen
Texas Oncology-Austin Central, Austin
Texas Oncology - Amarillo, Amarillo
Texas Oncology -El Paso, El Paso
Arizona Oncology Associates, Tucson
Arizona Oncology Associates, Tuscon
University of New Mexico Cancer Center, Albuquerque
Memorial Medical Center, Las Cruces
Comprehensive Cancer Centers of Nevada, Henderson
Wilshire Oncology Medical Group, Rancho Cucamonga
PMK Medical Group, Oxnard
Marin Cancer Center, Greenbrae
Northwest Cancer Specialists, Portland
Puget Sound Cancer Center, Seattle
Yakima Valley Memorial Hospital, Yakima
Dana-Farber Cancer Institute, Boston
Dana Farber Cancer Institute, Boston
Cooper Cancer Institute, Voorhees Township
Texas Oncology Plano East, Plano
Lead Sponsor
Collaborators (1)
Sanofi
INDUSTRY
Merrimack Pharmaceuticals
INDUSTRY